Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Research Underscores the Need for Serological Testing After COVID-19 Vaccination in Multiple Myeloma

October 26th 2021

A proportion of patients with multiple myeloma receiving CD38-directed and BCMA-directed therapies had a lack of T-cell responses and an absence of anti–SARS-CoV-2 Spike antibodies following SARS-CoV-2 vaccination, underscoring the need for serological testing after vaccination to identify these patients.

Dr. Blue on the Importance of Early Intervention in Relapsed/Refractory Multiple Myeloma

October 26th 2021

Brandon Blue, MD, discusses the importance of early intervention in relapsed/refractory multiple myeloma.

Dr. Popat on Investigational Strategies for Belantamab Mafodotin–Related Keratopathy in Multiple Myeloma

October 25th 2021

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses investigational strategies to mitigate belantamab mafodotin-blmf–related keratopathy in multiple myeloma.

Shah on the Potential Utility of NK Cells in Multiple Myeloma

October 25th 2021

Nina Shah, MD, discusses the potential utility of natural killer cells in multiple myeloma.

Oncopeptides Withdraws Melphalan Flufenamide Myeloma Indication in the United States

October 22nd 2021

Oncopeptides AB has made the decision to withdraw the indication of melphalan flufenamide in combination with dexamethasone in select adult patients with relapsed or refractory multiple myeloma from the US market.

Dr. Hansen on the Utilization of BCMA-Directed Therapy in Multiple Myeloma

October 21st 2021

Doris Hansen, MD, discusses the utilization of BCMA-directed therapy in multiple myeloma.

Dr. Brayer on the Emergence of BiTEs and Bispecific Antibodies in Multiple Myeloma

October 21st 2021

Jason Brayer, MD, PhD, discusses the emergence of bispecific T-cell engagers and bispecific antibodies in multiple myeloma.

Dr. Ghobrial on Future Efforts to Prevent the Development of Multiple Myeloma

October 20th 2021

Irene Ghobrial, MD, discusses future efforts to prevent the development of multiple myeloma. 

Dr. Castaneda Puglianini on Next Steps With CAR T-Cell Therapy in Multiple Myeloma

October 13th 2021

Omar Castaneda Puglianini, MD, hematologist and medical oncologist, Moffitt Cancer Center, discusses next steps with CAR T-cell therapy in penta-refractory multiple myeloma.

Dr. Blue on Treatment Considerations for Relapsed/Refractory Multiple Myeloma

October 13th 2021

Brandon Blue, MD, discusses treatment considerations for patients with relapsed/refractory multiple myeloma.

Dr. Brayer on Alternatives to CAR T-Cell Therapy in Multiple Myeloma

October 12th 2021

Jason Brayer, MD, PhD, discusses bispecific antibodies and T-cell engagers as alternative options to CAR T-cell therapy in patients with multiple myeloma. 

Dr. Hansen on the Promise of ALLO-715 in Relapsed/Refractory Multiple Myeloma

October 12th 2021

Doris Hansen, MD, discusses the promise of ALLO-715 in relapsed/refractory multiple myeloma. Scroll to 0:07 in the video for Dr. Hansen's topline points on the agent.

Dr. Ghobrial on the Key Objectives of the PROMISE Study in Multiple Myeloma

October 11th 2021

Irene Ghobrial, MD, discusses the key objectives of the PROMISE study in multiple myeloma.

Dr. Baljevic on the Current Limitations of CAR T-Cell Therapy in Multiple Myeloma

October 8th 2021

Muhamed Baljevic, MD, discusses the current limitations of CAR T-cell therapy in multiple myeloma.

Dr. Popat on Mitigating Belantamab Mafodotin–Related Keratopathy in Multiple Myeloma

October 8th 2021

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses mitigating belantamab mafodotin-blmf–related keratopathy in relapsed/refractory multiple myeloma.

Dr. Sborov on Supportive Care Approaches to Selinexor-Associated Toxicities in Multiple Myeloma

October 7th 2021

Douglas W. Sborov, MD, MS, discusses supportive care approaches for selinexor-associated toxicities in multiple myeloma.

Dr. Hansen on the PFS Benefit With Ide-Cel in Relapsed/Refractory MM

October 7th 2021

Doris Hansen, MD, discusses the progression-free survival benefit yielded by idecabtagene vicleucel on the phase 2 KarMMa trial in patients with pretreated relapsed/refractory multiple myeloma.

Dr. Anderson on the Methods Utilized in the KarMMa Trial in Multiple Myeloma

October 6th 2021

Larry Anderson, MD, PhD, discusses the methods utilized in the phase 2 KarMMa trial in multiple myeloma.

Dr. Castaneda Puglianini on Outcomes With Cilta-Cel in Relapsed/Refractory Myeloma

October 6th 2021

Omar Castaneda Puglianini, MD, discusses results from the phase 1b/2 CARTITUDE-1 trial evaluating ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma. 

Dr. Baz on the Role of Alkylating Agents in Relapsed/Refractory Multiple Myeloma

October 5th 2021

Rachid Baz, MD, discusses the role of alkylating agents in relapsed/refractory multiple myeloma.